Susquehanna International Group’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-749,300
| Closed | -$4.52M | – | 11345 |
|
|
2019
Q4 | $4.52M | Buy |
749,300
+449,700
| +150% | +$2.6M | ﹤0.01% | 3114 |
|
|
2019
Q3 | $1.08M | Buy |
299,600
+248,200
| +483% | +$957K | ﹤0.01% | 5529 |
|
|
2019
Q2 | $138K | Sell |
51,400
-3,600
| -7% | -$10.6K | ﹤0.01% | 9432 |
|
|
2019
Q1 | $163K | Buy |
+55,000
| New | +$135K | ﹤0.01% | 7990 |
|
|
2018
Q4 | – | Sell |
-74,000
| Closed | -$272K | – | 10465 |
|
|
2018
Q3 | $272K | Sell |
74,000
-27,600
| -27% | -$82.3K | ﹤0.01% | 7668 |
|
|
2018
Q2 | $288K | Buy |
101,600
+39,200
| +63% | +$134K | ﹤0.01% | 7923 |
|
|
2018
Q1 | $232K | Buy |
62,400
+48,300
| +343% | +$158K | ﹤0.01% | 8082 |
|
|
2017
Q4 | $41K | Sell |
14,100
-51,600
| -79% | -$187K | ﹤0.01% | 8960 |
|
|
2017
Q3 | $295K | Buy |
65,700
+19,200
| +41% | +$85.2K | ﹤0.01% | 7429 |
|
|
2017
Q2 | $213K | Buy |
46,500
+24,300
| +109% | +$97.7K | ﹤0.01% | 8189 |
|
|
2017
Q1 | $93K | Sell |
22,200
-203,500
| -90% | -$845K | ﹤0.01% | 8421 |
|
|
2016
Q4 | $932K | Sell |
225,700
-56,300
| -20% | -$299K | ﹤0.01% | 5680 |
|
|
2016
Q3 | $2.28M | Sell |
282,000
-144,300
| -34% | -$1.23M | ﹤0.01% | 3338 |
|
|
2016
Q2 | $3.33M | Sell |
426,300
-78,400
| -16% | -$673K | ﹤0.01% | 2774 |
|
|
2016
Q1 | $3.9M | Sell |
504,700
-230,100
| -31% | -$1.69M | ﹤0.01% | 2649 |
|
|
2015
Q4 | $7.93M | Sell |
734,800
-258,300
| -26% | -$2.35M | ﹤0.01% | 1993 |
|
|
2015
Q3 | $6.86M | Sell |
993,100
-290,900
| -23% | -$2.37M | ﹤0.01% | 2260 |
|
|
2015
Q2 | $11.4M | Sell |
1,284,000
-232,400
| -15% | -$2.2M | ﹤0.01% | 1854 |
|
|
2015
Q1 | $15M | Sell |
1,516,400
-1,252,000
| -45% | -$15.6M | 0.01% | 1492 |
|
|
2014
Q4 | $33.9M | Buy |
2,768,400
+846,900
| +44% | +$10.3M | 0.01% | 958 |
|
|
2014
Q3 | $19.2M | Buy |
1,921,500
+563,700
| +42% | +$5.23M | 0.01% | 1456 |
|
|
2014
Q2 | $10.3M | Buy |
1,357,800
+721,400
| +113% | +$2.88M | ﹤0.01% | 2090 |
|
|
2014
Q1 | $2.09M | Sell |
636,400
-865,300
| -58% | -$3.03M | ﹤0.01% | 4267 |
|
|
2013
Q4 | $4.99M | Sell |
1,501,700
-765,000
| -34% | -$2.22M | ﹤0.01% | 2951 |
|
|
2013
Q3 | $6.84M | Buy |
2,266,700
+1,435,100
| +173% | +$9.84M | ﹤0.01% | 2309 |
|
|
2013
Q2 | $6.8M | Buy |
+831,600
| New | +$6.35M | ﹤0.01% | 2234 |
|
Susquehanna International Group's ACHN Position: Q1 2020 in Review
Susquehanna International Group sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 15,357 shares — an estimated $93K sold.
Susquehanna International Group first reported a position in ACHN in Q2 2013 and held it in 25 quarters. The position peaked at $6.83M in Q1 2015. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Susquehanna International Group reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Susquehanna International Group sold 15,357 Achillion Pharmaceuticals shares in Q1 2020, an estimated $93K.
- Susquehanna International Group first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 25 quarters.
- Susquehanna International Group's Achillion Pharmaceuticals position peaked at $6.83M in Q1 2015.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Susquehanna International Group's 13F filing for Q1 2020, filed 15 May 2020.